Recent News

FY22 R&D Registrations Now Open

July 1st, 2022

Companies are now able to register R&D activities conducted during the year ended 30 June 2022 (FY22) with AusIndustry. For the FY22 period, the application process is again administered through the new online customer portal which was introduced for the prior FY21 period. There were substantial changes made to the R&D activity technical description requirements in FY21, however the AusIndustry activity disclosure requirements for FY22 appear not to have materially changed. The big changes for FY22 R&D c laims relate […]

Read More

Pure Hydrogen Corporation Provides Update on Settlement of Dispute to Repay R&D Tax Refund

June 27th, 2022

As previously reported, Real Energy Ltd was involved in a dispute with R&D Tax Incentive programme regulators over the eligibility of its R&D activities spanning a number of years. Corporate activity between Real Energy and Strata-X has since merged to form Pure Hydrogen Corporation Ltd. Pure Hydrogen Corporation on the 23rd of June provided the following update on the dispute: The matter was taken to the Administrative Appeals Tribunal over 3 years ago and now the parties have consented to […]

Read More

R&D Tax Incentive – Reminder of Key Points Before 30 June

June 24th, 2022

Companies planning registration of R&D activities in the FY22 period (for the YE 30 June 2022) should be mindful of the following before the upcoming end of the financial year: Findings for overseas activities: Companies seeking to claim expenditure for overseas activity in their FY22 R&D claims must apply to claim these costs by lodging an Overseas Finding Application before the end of the financial year (i.e. 30 June). In addition to general eligibility criteria, there are specific and extensive […]

Read More

Paradigm Biopharmaceuticals (ASX:PAR) Received $8.2m R&D Tax Refund

June 13th, 2022

Melbourne based Paradigm Biopharmaceuticals has reported receipt of a $8.2 million research and development tax incentive refund for the YE 30 June 2021 relating to ongoing R&D activities into its pentosan polysulfate sodium treatment. The company has advised that the funds will be reinvested in R&D activities and to support its global Phase 3 and Phase 2 clinical programs. Paradigm Biopharmaceuticals’ R&D offset refund is one of the larger R&D tax offsets reported, alongside the likes of Telix Pharmaceuticals’ R&D […]

Read More